We were incorporated in Malaysia under the Companies Act 1965 on 27 July 2016 as a private limited company under the name of Nova Wellness Group Sdn Bhd. The Company is also deemed registered under the Act as at 31 January 2017. We subsequently converted to a public limited company on 31 October 2017 to facilitate our Listing.
Our principal activity is in investment holding while our subsidiary, Nova Laboratories is principally involved in the development, production and sales of nutraceutical and skincare products; and OEM development and production of nutraceutical products.
Board of Directors
Dr Abdul Manaf bin Mohamad Radzi is our Independent Non-Executive Chairman. He was appointed to our Board on 31 October 2017 and is the Chairman of our Remuneration and Nomination Committees and a member of our Audit and Risk Management Committees.
He graduated with a Bachelor of Science in Chemistry with a minor in Physics from Northern Illinois University, United States of America in 1977. In 1987, he obtained a Doctor of Philosophy in Physical Chemistry and minor in Inorganic Chemistry from the University of Tennessee, Knoxville, United States of America. He then obtained a Master of Business Administration from the Ohio University, United States of America in 1996.
He started his career in 1977 as a researcher at the chemistry laboratory in Northern Illinois University until 1980. He then furthered his studies from 1981 until 1987, attaining the Doctor of Philosophy in Physical Chemistry and minor in Inorganic Chemistry as mentioned above. Subsequently in 1988, he joined ICI Fertilizers Sdn Bhd as a technical executive and was subsequently promoted to marketing executive of the company in 1990. In 1992, he left ICI Fertilizers Sdn Bhd to join PETRONAS Petroleum Research Institute (now known as PETRONAS Research & Scientific Services Sdn Bhd) as an agrochemical executive before he was transferred to the Malaysian International Trading Corporation Sdn Bhd (a subsidiary of PETRONAS Research Sdn Bhd) in 1994 as a trader for urea and agrochemicals in Vietnam.
In 1995, he left Malaysian International Trading Corporation Sdn Bhd to join FRC Manufacturing (M) Sdn Bhd as a technical executive. In 1996, he left FRC Manufacturing (M) Sdn Bhd and joined ACP Industries Berhad as a manager in its special projects division, where he provided technical advice on new product development of the company.
In 2004, he left ACP Industries Berhad to join the education sector and became a lecturer in Sunway College Sdn Bhd. He left the education sector in 2005 to join Chemical Company of Malaysia Berhad as its Group Market Development Manager where he was responsible for identifying and developing market demands for the company’s products. He was subsequently promoted to senior manager in 2006. In 2007, he was again promoted and was transferred to CCM Duopharma Biotech Berhad (subsidiary of Chemical Company of Malaysia Berhad) as its general manager and in that capacity was responsible for the international sales for the company’s export operations until 2009.
In November 2009, he joined Innovax Sdn Bhd as the chief scientific officer responsible for R&D of pharmaceutical products before joining Malaysian Bioeconomy Development in January 2010 as the senior vice-president of its industrial division. In February 2010, he was transferred to the agriculture biotechnology division before being reassigned to the special projects division in 2012. In 2015, he became the senior vice-president of University-Industry Partnership division in Malaysian Bioeconomy Development and he was also a member of Scientific Advisory Board of Bioalpha Holdings Berhad before retiring in 2017.
Phang Nyie Lin is our co-founder, Promoter, Managing Director and Chief Research Officer. He was appointed to our Board on 31 October 2017.
Phang Nyie Lin graduated with a Bachelor of Pharmacy from Universiti Sains Malaysia, Malaysia in 1980. Upon his graduation in 1980, he started his career as a pharmacist trainee in the pharmacy department of Ipoh General Hospital, Perak (now known as Hospital Raja Permaisuri Bainun). He became a registered pharmacist with the MOH after he completed his training in 1981. In 1983, he was transferred to the National Tuberculosis Centre (now known as the Department of Respiratory Medicine, Hospital Kuala Lumpur) to serve as a pharmacist.
In 1985, he left the National Tuberculosis Centre to set up Farmasi Sepadu, a community pharmacy in Sungai Pelek, Selangor, which was involved in the distribution of animal health products to livestock farms. Farmasi Sepadu ceased its operations in 1988. In 1989, he established Nova Laboratories which initially was involved in the trading of animal health products and subsequently expanded its operations to undertake the production of nutraceutical products in 2002. Nova Laboratories discontinued its veterinary business on 9 January 2017. As our Managing Director, he is responsible for providing the strategic direction and overseeing the overall business operations of our Group. He also holds the position of Chief Research Officer of our Group and in that capacity is responsible for overseeing all R&D activities including conceptualising ideas for new product developments and re-formulation of existing products.
As our Chief Research Officer and a qualified pharmacist, he leads our R&D activities and has been involved in various research projects. Our R&D activities mainly involve research of natural botanical ingredients and developing new products and improving existing products of our Group. Under his leadership, we developed and commercialised a patented liver tonic known as Hepar-P Capsule. Further, we also developed our own sustained-release glucosamine caplet in 2005 and developed the Actisof formulation in 2008 to enhance the body’s absorption of oil-based ingredients, which is widely applied in all of our softgel products. With 20 years of experience in the local nutraceutical industry, he is the driving force behind Nova Laboratories since its incorporation, which is now producing and retailing 56 nutraceutical products and 24 skincare products locally and overseas under our House Brands.
He also developed a patented product formulation containing Calanolide A (a compound isolated from a tropical tree, Callophyllum lanigerum) which is an anti-human immunodeficiency virus (HIV) drug on behalf of Nova Laboratories for CRAUN Research Sdn Bhd, Sarawak. Calanolide A was granted patents in Malaysia, Indonesia, Singapore, Australia, Hong Kong, Korea and China. All the patents to the product belong to CRAUN Research Sdn Bhd.
Phang Yeen Nung is our Promoter and Executive Director. He was appointed to our Board on 31 October 2017.
From 2006 to 2007, he underwent and completed an English For Academic Purposes course at Canterbury Christ Church University. In 2008, he did a Law Foundation course at Bellerbys College, United Kingdom. He then commenced his Bachelor of Laws at the University of Kent, United Kingdom in 2009, which he completed in 2012. Upon graduation in 2012, he joined Nova Laboratories as a marketing executive and in that capacity was responsible for developing new marketing initiatives, assessing new market needs and identifying new business opportunities in the market.
In 2014, he assumed his role in business development and was in charge of identifying and securing new business contracts, and building and maintaining customer relationships for our Group.
Phang Yeen Aun is our Promoter and Executive Director. He was appointed to our Board on 31 October 2017.
Phang Yeen Aun graduated from the International Medical University, Malaysia with a Bachelor of Pharmacy in 2009. Upon graduation, he started his career in 2010 as a pharmacist trainee in the pharmacy department of Hospital Tuanku Ja’afar, Seremban until 2011. Subsequently in 2011, he joined Nova Laboratories as a marketing executive and in that capacity was responsible for developing and executing new marketing plans and promotion campaigns for our products and the “Nova” brand in the industry. He resigned as marketing executive in Nova Laboratories at the end of 2011.
In 2012, he joined Nutraphyll as Managing Director where he was responsible for providing the strategic direction and overseeing the overall business operations of Nutraphyll. Nutraphyll owned and operated six health store outlets exclusively selling our House Brand products. As set out in Section 10.2.1, Nutraphyll was previously controlled by our Promoters through their shareholdings and directorships in Nutraphyll until August 2017. In 2017, he left Nutraphyll for a marketing role in Nova Laboratories, where he oversees the marketing activities of our Group. At present, apart from his marketing role, he also plays a key role in R&D activities, particularly in product formulation.
Dr Munavvar Zubaid bin Abdul Sattar is our Independent Non-Executive Director. He was appointed to our Board on 31 October 2017 and is a member of our Remuneration Committee.
He graduated from the Universiti Sains Malaysia, Malaysia with a Bachelor of Pharmacy in 1980 and a Master of Science in Pharmacy in 1984. He obtained a Doctor of Philosophy in Physiology from the University of Birmingham, United Kingdom in 1993.
He started his career as a pharmacist in the pharmacy department of Kuala Terengganu Hospital, Terengganu (now known as Hospital Sultanah Nur Zahirah) in 1980. In 1982, he left Kuala Terengganu Hospital to join the education sector to become a graduate research assistant at the School of Pharmaceutical Sciences in Universiti Sains Malaysia.
He subsequently became a lecturer in 1984 and an associate professor in 1996. His last position at Universiti Sains Malaysia was as professor and dean of School of Pharmaceutical Sciences, Universiti Sains Malaysia. He left in 2017 and joined MAHSA University as professor and dean of Faculty of Pharmacy, a position he still holds.
As a professor, he has pioneered various research projects which have been published in various international journals, mainly in the area of physiology and pharmacology. His main research areas are neural control of kidney function, gene therapy as drug of the future as well as herbal pharmacological and toxicological evaluation and formulation. In 2001, he was appointed to the editorial board of the Malaysian Journal of Pharmaceutical Science and still sits on it.
Sulaiman bin Haji Ahmad is our Non-Independent Non-Executive Director. He was appointed to our Board on 31 October 2017 and is a member of our Remuneration and Nomination Committees.
He graduated from Universiti Sains Malaysia, Malaysia with a Bachelor of Pharmacy in 1981. He became a registered pharmacist with the MOH after he completed his training in 1982. He started his career as a pharmacist in the manufacturing unit of the Sabah Central Medical Store and Hospital Queen Elizabeth, Sabah in 1982. In 1985, he was transferred to the National Pharmaceutical Control Bureau (now known as NPRA) as an analytical pharmacist responsible for product analysis. In 1990, he was promoted to senior pharmacist and was subsequently transferred to the GMP division of the National Pharmaceutical Control Bureau as a GMP auditor responsible for conducting GMP audits. In 2005, he was promoted to Head of Department of Compliance and Licensing for the GMP division until 2008.
In 2008, he was transferred to Hospital Klang, Selangor as chief pharmacist and the head of its pharmacy department. In 2009, he was transferred to Hospital Raja Permaisuri Bainun, Perak as chief pharmacist and the head of its pharmacy department. In 2010, he was promoted and transferred back to National Pharmaceutical Control Bureau as Deputy Director to lead its GMP and licensing division. He retired from his role as Deputy Director in 2016.
Sim Seng Loong @ Tai Seng is our Independent Non-Executive Director. He was appointed to our Board on 31 October 2017 and is the Chairman of our Audit Committee and Risk Management Committee.
He was admitted as a member of the Malaysian Institute of Certified Public Accountants since May 1994, a Chartered Accountant under the Malaysian Institute of Accountants since March 1995 and as a member of the CPA Australia since March 2008.
He began his career as an auditor, with Ernst & Young, Kuala Lumpur in 1988 where he was tasked with the execution of audit assignments. During his employment with Ernst & Young, he entered into a four-year training contract with Lim Ali & Co from September 1988 until September 1992 to pursue his CPA.
Upon completion of his contract with Lim Ali & Co, he stayed on in Ernst & Young from 1992 until 2004. During his employment with Ernst & Young, he was tasked with audit assignments of various industries including those of government linked entities and other corporate finance assignments. In 2004, he started his own firm, R.K. Associates as lead partner where he was responsible for the day-to-day operations of the firm as well as audit and reporting work of various companies. In 2007, he joined Eaton Industries Pty. Ltd. (Australia) as a corporate accountant where he was tasked to co-ordinate the company’s world-wide restructuring exercise. He was transferred to Shanghai Eaton Engine Components Ltd, China in 2009 as a financial controller. After leaving Shanghai Eaton Engine Components Ltd in 2010, he took a hiatus until January 2012. He then joined The BIG Group Sdn Bhd in January 2012, as CFO and chief operating officer before leaving in 2013. During his time at The BIG Group Sdn Bhd, he was primarily responsible for the finance and information technology function of the company and as well as day-to-day operations which also includes new restaurant openings.
In 2013, he was appointed as CFO of Petrol One Resources Berhad and in 2014, he was appointed as an independent director of Pentamaster Corporation Berhad. In 2015, he was appointed as a director of Petrol One Holdings Sdn Bhd and in 2016, he was also appointed as a non-executive independent director of Jack-In Group Limited which is listed on the Australian Stock Exchange.
He ceased to be the non-executive independent director of Jack-In Group since July 2020.
Tan Mio Har is our Independent Non-Executive Director. She was appointed to our Board on 31 October 2017 and is a member of our Audit Committee and Risk Management Committee. She is the chairman for the Nomination Committee and Remuneration Committee.
She obtained her Diploma in Business Studies in Accounting from Tunku Abdul Rahman College, Malaysia in 2003. Upon graduation, she commenced her Association of Chartered Certified Accountants qualification, which she completed in 2007. She has been a member of the Association of Chartered Certified Accountants since 2011 and she was admitted as a fellow of Association of Chartered Certified Accountants in May 2016. She has also been a member of the Malaysian Institute of Accountants since 2016.
She began her career as an auditor with Adrian Yeo & Co in 2007 where she performed auditing work on companies in various industries. In 2009, she left the company to join Palm Gold Corporation Sdn Bhd as an internal audit executive where she performed risk-based internal audits and reviewed the suitability and compliance of the company’s internal control policies and procedures.
In 2012, she left Palm Gold Corporation Sdn Bhd and joined ST Rock Blasting Sdn Bhd as an accountant where her responsibilities include handling financial accounts and taxation matters as well as preparing analytical reviews of the company’s finance operations, a position she still holds.